A randomized trial of basiliximab with three different patterns of cyclosporin A initiation in renal transplant from expanded criteria donors and at high risk of delayed graft function

• Published in: Clinical transplantation 2009-01, Vol.23 (1), p.23-32
• Main Authors: Andrés, Amado, Marcén, Roberto, Valdés, Francisco, Sánchez Plumed, Jaime, Solà, Ricard, Errasti, Pedro, Lauzurica, Ricardo, Pallardó, Luis, Bustamante, Jesús, Amenábar, Juan José, Plaza, Juan José, Gómez, Ernesto, Grinyó, Josep Maria, Rengel, Manuel, Puig, Josep Maria, Sanz, Aurelio, Asensio, Concepción, Andrés, Inés
• Format: Article
• Language: English
• Subjects: acute rejection; Antibodies, Monoclonal - therapeutic use; basiliximab; Biological and medical sciences; cyclosporin A; Cyclosporine - therapeutic use; Delayed Graft Function; Drug Therapy, Combination; Female; Fundamental and applied biological sciences. Psychology; Fundamental immunology; Graft Rejection - drug therapy; Graft Rejection - immunology; Graft Survival - drug effects; Humans; Immunosuppressive Agents - therapeutic use; Kidney Function Tests; Kidney Transplantation; Male; Medical sciences; Middle Aged; Mycophenolic Acid - analogs & derivatives; Mycophenolic Acid - therapeutic use; Prospective Studies; Recombinant Fusion Proteins - therapeutic use; renal transplant; Risk Factors; Surgery (general aspects). Transplantations, organ and tissue grafts. Graft diseases; Survival Rate; Tissue, organ and graft immunology; Treatment Outcome
• ISSN: 0902-0063; 1399-0012
• DOI: 10.1111/j.1399-0012.2008.00891.x

:  This study assays therapy with basiliximab and different patterns of cyclosporin A (CsA) initiation in renal transplant (RT) recipients from expanded criteria donors (ECD) and at high risk of delayed graft function (DGF). A multicentre six‐month open‐label randomized trial with three parallel groups treated with basiliximab plus steroids, mycophenolate mofetil and different patterns of CsA initiation: early within 24 h post‐RT at 3 mg/kg/d (Group 1; n = 38), and at 5 mg/kg/d (Group 2; n = 40), or delayed after 7–10 d at 5 mg/kg/d (Group 3; n = 36). There were no differences among groups in six months GFR (43.1 ± 12, 48.0 ± 14 and 47.2 ± 17 mL/min, respectively), DGF (Group 1: 31%, Group 2: 37%, Group 3: 42%), nor biopsy‐proven acute rejection, although clinically treated and biopsy‐proven acute rejection was significantly higher in Group 3 (25%) vs. Group 1 (5.3%, p